Company overview
Indero is a dual-focus contract research organization (CRO) specializing in dermatology and rheumatology clinical trials, offering end-to-end services from early to late phase. Services include patient recruitment, medical monitoring, and innovative methods like quantitative gene expression for topical drug evaluation. They also support aesthetics and cosmetics trials with global reach and therapeutic expertise.
Indero is listed in the NovaPharmaNews Supplier Hub as a CRO & Clinical Services partner serving United States & Americas. Core focus areas include dermatology cro, rheumatology cro, clinical trials, patient recruitment, medical monitoring.
Industry categories: CRO & Clinical Services. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Indero include Cro — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://inderocro.com
- Categories
- CRO & Clinical Services
- Markets served
- United States & Americas
- Keywords
- dermatology cro, rheumatology cro, clinical trials, patient recruitment, medical monitoring
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What therapeutic areas does Indero specialize in?
- Indero specializes in dermatology and rheumatology, with additional expertise in aesthetics and cosmetics clinical trials.
- What phases of clinical trials does Indero support?
- Indero provides end-to-end services covering both early-phase and late-phase clinical trials in dermatology and rheumatology.
- What are Indero's key services for clinical trials?
- Key services include patient recruitment strategies, medical monitoring for safety and data integrity, and innovative early-phase evaluation methods using quantitative gene expression analysis.
Related editorial coverage
- Lilly buys 4E in non-opioid pain push: what investors should watch
- America's Innovation Engine: Small and Mid-Sized Biotechs Drive U.S. Clinical Trials, FDA Filings
- Friday Five: ASCO Takeaways, ADA Focus, China Deals & More – Clinical Trials
- FDA Extends Comment Period for Real-Time Clinical Trials Pilot, AI Use in Studies
- Uncertain FDA Leadership Raises Stakes in Clinical Trials: A Strategic Overview
- FDA's Shifting Tides: Navigating Clinical Trials Amidst Regulatory Uncertainty
Explore lab tools and QA/QC resources for R&D teams.
